Gufic Biosciences

Jan 20 (Reuters) - Gufic Biosciences Ltd GUFI.NS:

• RECEIVES TAX DEMAND NOTICE FOR 43.3 MILLION RUPEES

Source text: ID:nBSE2cfC1B

Further company coverage: GUFI.NS

(([email protected];;))

Jan 13 (Reuters) - Gufic Biosciences Ltd GUFI.NS:

• GUFIC BIOSCIENCES LTD - GUFIC BIOSCIENCES INVESTS AED 200,000 IN UNIT VEIRA LIFE FZE

Source text: ID:nBSE1j770C

Further company coverage: GUFI.NS

(([email protected];))

** Shares of Gufic Biosciences GUFI.NS slip 6.1% to 418.50 rupees

** The pharmaceuticals co's Q2 consol total profit fell 6.2% y/y, revenue down 5% y/y

** Strategic initiatives,including increase in overall market share in Botulinum Toxin products, investments in new biological technology platform and commercialization of immuno-oncology therapy to boost growth over next few years, co says

** Stock up ~32% YTD

(Reporting by Vijay Malkar)

(([email protected];))

Nov 14 (Reuters) - Gufic Biosciences Ltd GUFI.NS:

• SEPT-QUARTER CONSOL TOTAL PROFIT 217.7 MILLION RUPEES

• SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 2.04 BILLION RUPEES

Source text: [ID:]

Further company coverage: GUFI.NS

(([email protected];;))

Aug 14 (Reuters) - Gufic Biosciences Ltd GUFI.NS:

• JUNE-QUARTER NET PROFIT FROM CONTINUING OPERATIONS 208.6 MILLION RUPEES

• JUNE-QUARTER REVENUE FROM OPERATIONS 2.03 BILLION RUPEES

• RE‐APPOINTMENT OF JAYESH CHOKSI AS CHAIRMAN, MD

Source text for Eikon: [ID:]

Further company coverage: GUFI.NS

(Reporting by VijayDattaram Malkar)

(([email protected];))

March 14 (Reuters) - Gufic Biosciences Ltd GUFI.NS:

• GRANTED PATENT FOR INVENTION ENTITLED LYOPHILIZED PHARMACEUTICAL COMPOSITIONS OF DALBAVANCIN

Source text for Eikon: [ID:]

Further company coverage: GUFI.NS

(([email protected];))

Feb 14 (Reuters) - Gufic Biosciences Ltd GUFI.NS:

• GUFIC BIOSCIENCES DEC-QUARTER TOTAL PROFIT 222.6 MILLION RUPEES VERSUS PROFIT 203.4 MILLION RUPEES

• GUFIC BIOSCIENCES DEC-QUARTER REVENUE FROM OPERATIONS 2.02 BILLION RUPEES VERSUS 1.77 BILLION RUPEES

Source text for Eikon: ID:nBSE5KSK8Y

Further company coverage: GUFI.NS

(([email protected];;))

Jan 30 (Reuters) - Gufic Biosciences Ltd GUFI.NS:

• CO GRANTED PATENT OF ADDITION FOR FREEZE DRIED PARENTERAL COMPOSITION OF OMADACYCLINE TOSYLATE

• GOT PATENT FOR 20 YEARS

Source text for Eikon: ID:nNSE1hr677

Further company coverage: GUFI.NS

(([email protected];))

Nov 9 (Reuters) - Gufic Biosciences Ltd GUFI.NS:

• INDIA'S GUFIC BIOSCIENCES SEPT-QUARTER NET PROFIT FROM CONTINUING OPERATIONS 232.1 MILLION RUPEES VERSUS 202.1 MILLION RUPEES

• GUFIC BIOSCIENCES LTD SEPT-QUARTER REVENUE FROM OPERATIONS 2.15 BILLION RUPEES VERSUS 1.75 BILLION RUPEES

Source text for Eikon: ID:nBSEbNyQpm

Further company coverage: GUFI.NS

(([email protected];))

Sept 27 (Reuters) - Gufic Biosciences Ltd GUFI.NS:

• APPROVED INCORPORATION OF UNIT IN DUBAI, UAE

Source text for Eikon: ID:nBSEcgCgsV

Further company coverage: GUFI.NS

(([email protected];;))

** Shares of Gufic Biosciences GUFI.NS up as much as 4.57% to 310 rupees

** Stock on track for third consecutive session of gains

** Active pharmaceutical ingredients maker said it has been granted 20-year patent for Omadacycline Tosylate, a component used in drugs

** About 201,355 shares change hands as of 10:42 a.m. IST, 0.5x 30-day average

** Stock up ~31% so far this year, as of last close

(Reporting by Manvi Pant in Bengaluru)

(([email protected]; +918447554364;))

Sept 14 (Reuters) - Gufic Biosciences Ltd GUFI.NS:

• GRANTED PATENT FOR INVENTION "FREEZE DRIED PARENTERAL COMPOSITION OF OMADACYCLINE TOSYLATE AND PROCESS FOR PREPARATION THEREOF"

• PATENT GRANTED FOR TERM OF 20 YEARS EFFECTIVE FROM APRIL 19, 2021

Source text for Eikon: ID:nBSE1rQVLF

Further company coverage: GUFI.NS

(([email protected];))

** Shares of Gufic Biosciences GUFI.NS rise as much as 7.6% to 319.2 rupees, biggest pct gain since July 27

** Co receives regulatory approval for Parecoxib 40 mg injection from Australia's TGA and Brazil's Anvisa

** Injection to be used for short-term treatment of acute pain and post-operative pain in adult patients

** More than 804,930 shares change hands by 11:20 a.m. IST, 2.0x the 30-day avg of 402,502 shares

** Stock last up 2.6%, bumping YTD gains to ~33%

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected] ; ( +91 8078332441))

Sept 11 (Reuters) - Gufic Biosciences Ltd GUFI.NS:

• GUFIC RECEIVES TGA AUSTRALIA AND ANVISA BRAZIL APPROVAL FOR PARECOXIB 40MG INJECTION

Source text for Eikon: ID:nBSE2z651g

Further company coverage: GUFI.NS

(([email protected];))

Sept 1 (Reuters) - Gufic Biosciences Ltd GUFI.NS:

• TO ISSUE SHARES TO MOTILAL OSWAL FINANCIAL SERVICES ON A PREFERENTIAL BASIS

• SHARE ISSUE WORTH 999.9 MILLION RUPEES

• ISSUE PRICE 300 RUPEES PER SHARE

Further company coverage: GUFI.NS

(([email protected];))

** Shares of active pharmaceutical ingredients (API) maker Gufic Biosciences Ltd GUFI.NS up as much as 6.6% to 247 rupees, their highest since May 20, 2022

** Co on Friday said it received approval from National Medical Products Administration (NMPA), China, for Prilocaine API, an amide-type local anaesthetic

** Co says approval will help in commercialisation of the product in China and help explore Chinese market

** Over 654,000 shares change hands by 10:02 a.m. IST, 4.0x the 30-day moving avg

** As of last close, stock up 2.3% so far this year

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

June 16 (Reuters) - Gufic Biosciences Ltd GUFI.NS:

• RECEIVED APPROVAL FROM NATIONAL MEDICAL PRODUCTS ADMINISTRATION, CHINA FOR PRODUCT PRILOCAINE (API)

Source text for Eikon: [ID:]

Further company coverage: GUFI.NS

(([email protected];))

May 30 (Reuters) - Gufic Biosciences Ltd GUFI.NS:

• GUFIC BIOSCIENCES LTD- CLEARED PHYSICAL AUDIT OF BRAZILIAN HEALTH REGULATORY AGENCY SUCCESSFULLY WITHOUT ANY OBSERVATION

• GUFIC BIOSCIENCES LTD- RECEIVED GOOD MANUFACTURING PRACTICES CERTIFICATE FROM ANVISA FOR GUJARAT PLANT

• GUFIC BIOSCIENCES LTD- WILL ENABLE CO TO EXPAND BUSINESS IN BRAZIL

Source text for Eikon: ID:nBSE94QRJp

Further company coverage: GUFI.NS

(([email protected];))

May 29 (Reuters) - Gufic Biosciences Ltd GUFI.NS:

• INDIA'S GUFIC BIOSCIENCES MARCH-QUARTER NET PROFIT FROM CONTINUING OPERATIONS 181.1 MILLION RUPEES VERSUS PROFIT 202.6 MILLION RUPEES

• GUFIC BIOSCIENCES MARCH-QUARTER REVENUE FROM OPERATIONS 1.73 BILLION RUPEES VERSUS 1.62 BILLION RUPEES

Further company coverage: GUFI.NS

(([email protected];;))